ANI PharmaceuticalsANIP.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, ANI Pharmaceuticals (ANIP.O) trades at a P/E of 15.40x, P/B of 2.78x, P/S of 1.70x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 2nd percentile over the trailing 10Y window (vs. 4th percentile over 3Y); P/B sits at the 35th percentile over the trailing 10Y window (vs. 18th percentile over 3Y); P/S sits at the 2nd percentile over the trailing 10Y window (vs. 2nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 25th percentile within its industry and the 40th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.74%, ranking at the 96th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 33.6 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here lean heavily on buybacks rather than cash dividends. ANI Pharmaceuticals operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: ANIP · ANIP
Want the full picture on whether ANI Pharmaceuticals (ANIP.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 15.40 | ||||||
| P/B (MRQ) | 2.78 | ||||||
| P/S (TTM) | 1.70 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.74% |